

GCC-Targeted CAR-T Cell Therapy for Metastatic Gastric Cancer

Amanda Lisby, MS


Adam Snook Laboratory

Department of Pharmacology and Experimental Therapeutics

Disclosures


• There are no relevant disclosures to the presentation

Impact




20% of people who die from cancer could be treated with GCC-targeted therapies


Guanylyl Cyclase C (GCC)








GCC Immunotherapy

















GCC CAR-T Cells in Colorectal Cancer







Magee et al. Cancer Immunol Res 2018; 6(5): 509-516.




Intestinal-Type Gastric Cancer



Normal Stomach




Intestinal-Type Gastric Cancer




Normal Intestine


GCC and Gastric Cancer



Primary Cancer




Metastatic Cancer



Normal Mucosae


Birbe et al. Human Pathology. 2016;36. Danaee et al. PLoS ONE. 2017;12.

GCC CAR-T Cell Efficacy in Gastric Cancer






Treated Tumors Maintain GCC Antigen Expression



Summary

- GCC-CAR T Cells are safe and effective in Human CRC Models
- GCC-CAR T Cells are *effective* in Human Gastric Cancer Models
- GCC-CAR T Cells may not be affected by common tumor escape-mechanisms
- Opportunity for GMP translation to treatment in the clinic



Contributors

Waldman-Snook Laboratory

- Adam Snook, PhD
- Scott Waldman, MD, PhD
- Trevor Baybutt
- Megan Weindorfer
- Rob Carlon
- Josh Barton
- Lara Cheslow
- Madison Crutcher
- Ariana Entezari
- John Flickinger
- Elinor Leong
- Jeff Rappaport
- Jagmohan Singh
- Alicja Zalewski

Thesis Committee

- Geoffrey Krampitz, MD, PhD
- Aleksandra Snyder, PhD
- Ulrich Rodeck, MD, PhD













Margaret Q Landenberger Research Foundation



Until every cancer is cured

GCC Compartmentalization





GCC Compartmentalization

Jefferson Health NCI - designated

